

## เอกสารอ้างอิง



1. Sigler JW, Bluhm GB, Duncan H, et al. Gold Salts in the Treatment of Rheumatoid Arthritis : A double blind study. Ann Intern Med 1974;80:21-26.
2. Cohen AS, Calkins E. Controlled Study of Chloroquine as an antirheumatic agent. Arthritis Rheum 1958;1:297-301.
3. Popert AJ, Meijers KE, Sharp J, Bier F. Chloroquine diphosphate in rheumatoid arthritis, A control study. Ann Rheum Dis 1961;20:18-35.
4. Freedman A. Chloroquine and rheumatoid arthritis. Short-term controlled trial. Ann Rheum Dis 1965;15:251-255.
5. Rinehart RE, Rosenbaum EE, Hopkins CE. Chloroquine therapy in rheumatoid arthritis. Northwest Med 1957;56:703-707.
6. Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis, A double-blind fold trial of treatment for one year. Ann Rheum Dis 1960;19:423-427.
7. Daves MJ, Dawes PT, Fouler PD, Clarke S, Fisher J, Shadforth MF. Should disease - modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991;30:451-454.

8. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis. *Arthritis Rheum* 1986;29:822-831.
9. McConkey B, Amos R, Butler E. Salazopyrin in rheumatoid arthritis. *Agent Actions* 1978;8:438-441.
10. McConkey B, Amos R, Durham S, et al. Salphasalazine in rheumatoid arthritis. *Br Med J* 1980;280:442-444.
11. Bird H, Dixon J, Pickup M. A biochemical assessment of sulphasalazine in rheumatoid arthritis. *J Rheumatol* 1982;9:36-45.
12. Hart LE, Tugwell P. The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis. *Postgrad Med J* 1989;65:905-912.
13. Adams EM, Yocum DE, Bell GL. Hydroxychloroquine in the treatment of rheumatoid arthritis. *Am J Med* 1983;75:321-326.
14. Fehlaueer CS, Carson CW, Cannon GW, et al. Methotrexate therapy in rheumatoid arthritis : 2 years retrospective follow up study. *J Rheumatol* 1989;16:307-312.
15. Weinblat ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. *N Eng J Med* 1985;312:818-822.

16. Weinstein A, Marlowe S, Kom J, Farouhar F. Low dose methotrexate treatment of rheumatoid arthritis. Long-term observations. *Am J Med* 1985;79:331-337.
17. Weinblat ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis : effects on diseases activity in a multicenter prospective study. *J Rheum* 1991;18:334-338.
18. Kremer JM, Lee JK. A longterm prospective study of the use of methotrexate in rheumatoid arthritis, update after a mean of fifty-three months. *Arthritis Rheum* 1988;31:577-584.
19. Kremer JM. Methotrexate therapy in the treatment of rheumatoid arthritis. *Rheum Dis Clin North Am* 1989;15:533-556.
20. Weinblatt ME, et al. Methotrexate in rheumatoid arthritis, Five-year prospective multicenter study. *Arthritis rheu* 1994;37:1492-1512.
21. Marrasut P, Goldstein R, et al. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid. *J Rheu* 1989;16(3):302-6.
22. Suarez-Almazor ME, Fitzgerald, et al. A randomized controled trail of parenteral methotrexate compared with sodium thiomalate (myocrisine) in treatment of rheumatoid arthritis, a randomized double blinded 26-week trail. *J rheu* 1989;16(3):302-6.



23. Rau R,Herborn G, et al. A double blinded randomized parallel trail of intramuscular gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheu 1990;18:328-33.
24. Rau R,Herborn G, et al. A double blinded comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: An interim report on 102 patients after 12 months. Seminars in arthritis and rheumatism 1991;21(2 suppl 1): 13-20.
25. Saag KG, et al. Low dose long term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. American J of Med 1994;96:115-123.

## ประวัติผู้ทำวิทยานิพนธ์



ชื่อ แพทย์หญิง จิรภา ตีวัฒนากุล

การศึกษา แพทยศาสตร์บัณฑิต จาก มหาวิทยาลัยเชียงใหม่ จบ ปีการศึกษา 2532

พ.ศ. 2532-2536 แพทย์ใช้ทุนสาขาอายุรศาสตร์ โรงพยาบาลสงขลานครินทร์

พ.ศ. 2536-ปัจจุบัน แพทย์ประจำบ้านต่อยอด (Fellow) ในหน่วยโรคข้อและรูมาติซึม (Rheumatology) ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์จุฬาลงกรณ์มหาวิทยาลัย

ภาคผนวก



Gold .....  
 Other .....

HN .....

Clinical Trial in Rheumatoid Arthritis

Date..... Drug .....

Name ..... Age ..... Sex M F

Medical illness and duration .....

Duration of Rheumatoid Arthritis .....years

Previous treatment .....

Failure partial response, Good response, Allergy .....

Pattern of R.A	Articular Symptom			Associated Symptom
	Mono	Pauci	Poly	
Initial Present				

Revised American Rheumatism Association criteria for rheumatoid arthritis  
 Four or more criteria must be present to diagnose rheumatoid arthritis :

A R A - Diagnostic Criteria	Yes	No
1. Morning stiffness for at least one hour and present for at least six weeks		
2. Swelling of three or more joints for at least six weeks		
3. Swelling of wrist, metacarpophalangeal or proximal interphalangeal joints for six or more weeks		
4. Symmetric joint swelling		
5. Hand roentgenogram changes typical of rheumatoid arthritis that must include erosions or unequivocal bony decalcification		
6. Rheumatoid nodules		
7. Serum rheumatoid factor by a method positive in less than 5 % of normals		

Presently on .....  
No. Drug given ..... Left .....

Duration of morning stiffness (min.)

0	1	2	3
<30	30 - 60	60 - 120	>120

On set of atigue (hour)

0	1	2	3
>3	2 - 3	1 - 2	<1

Walking - time (25 feet) .....sec.      ESK .....

Grip strength

LT - hand

RT - hand

Mean    1<sup>st</sup>    2<sup>nd</sup>    3<sup>rd</sup>

1<sup>st</sup>    2<sup>nd</sup>    3<sup>rd</sup>    Mean

--	--	--	--

--	--	--	--

if patient is able to grip, do not subtract from the recorded reading  
if patient is unable to grip, record a reading to 20







Extra articular

- Subcutaneous nodule
- Heart - Pericarditis, Pericardial effusion, Cardiomyopathy, Conduction defect
- Lung - Plurisy, Plural effusion, Other.....
- Eye - Scleritis, Scleromalacia perforans, Iridocyclitis
- Nervous system .....
- Vasculitis .....
- Systemic - Anemia, Generalized osteoporosis, Felty's syndrome, Sjogren syndrome, Amyloidosis, Lymphopathy

ARA - Functional class - Evaluation	
1. Class I :	Complete : ability to carry on all usual duties without handicaps
2. Class II :	Adequate for normal activities : despite handicap of discomfort or limited motion at one or more joints
3. Class III :	Limited : only to little or none of duties of usual occupation or self care
4. Class IV :	Incapacitated, largely or wholly : Bedridden or confined to wheelchair : little or no self care

ARA Anatomical stage - Evaluation			
	Must be present	May be present	Must be absent
1. Stage I		Osteoporosis	Bone and cartilage destruction
2. Stage II	Osteoporosis	Limitation of motion bone and cartilage destruction Adjacent muscle atrophy nodules, Tenosynovitis	Joint deformity
3. Stage III	Bone and cartilage destruction joint deformity	Adjacent muscle atrophy, Nodules, Tenosynovitis	
4. Stage IV	Fibrous or bony destruction		

Total Evaluation

Investigator

Patient

4	3	2	1
Very good	Good	Fair	Poor

4	3	2	1
Very good	Good	Fair	Poor

Side effect and Toxicity

- Cutaneous - Pruritus, Rash, Exfoliative, Other .....
- Mucous membrane - Ulceration, bleeding
- Renal - proteinuria, Hematuria, nephrotic syndrome
- Hematologic - Leucopenia ( WBC < 3500 ), Thrombocytopenia ( PLT < 100,000 ) agranulocytosis, Aplastic anemia
- GI - Nausea, Vomiting, Diarrhea, constipation, abdominal pain, bleeding
- Other .....

Laboratory Test

- CBC : Hb ..... Hct ..... WBC ..... N ..... L .....  
 E ..... Platelet ..... ESR ..... M ..... B .....
- Urine : Alb ..... Sugar ..... WBC ..... RBC ..... Cast .....
- Stool : Occult blood ..... Parasite .....
- Blood other : BUN ..... Cr ..... FBs ..... Uric acid .....  
 SGOT ..... SGPT ..... Alk PO<sub>4</sub> ..... Bil .....  
 R.F ..... ANF ..... CH<sub>50</sub> ..... B<sub>1</sub>C .....
- Other .....